Contemporary randomized clinical trials assessing invasive CV interventions are often small with short follow-up and limited power to identify large treatment effects, according to a study published in JAMA Internal Medicine.
The study also found that commercially supported trials were linked to differences in results, design and reporting. In particular, commercially supported trials were more likely to report favorable outcomes than other trials, and to report findings inconsistent with the trial results.
In this cross-sectional study, Mario F.L. Gaudino, MD, FEBCTS, Stephen and Suzanne Weiss Professor of Cardiothoracic Surgery at Weill Cornell Medicine, and colleagues analyzed data from 216 randomized clinical trials focused on vascular, coronary and structural interventional cardiology and vascular and cardiac surgeries.